Benzinga · Sep 9, 2026
BTIG Reiterates Buy on Nektar Therapeutics, Maintains $178 Price Target
BTIG analyst Julian Harrison reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $178 price target.
NK
NASDAQ · NKTR
Nektar Therapeutics
Healthcare · Biotechnology
$66.64
Down-$1.86 (-2.72%)
Updated Sep 16, 2026, 12:50 PM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.04B
- P/E ratio
- -8.02
- Dividend yield
- 0.00%
- 52-week range
- $54.13 – $109.00
- Volume
- 1.26M
- Avg. volume
- 882.67K
Price performance
NKTR price history
1M range · 20 trading sessions · Daily adjusted prices
NKTR closed at $66.64 after 20 trading sessions, down 9.51% for the selected period.
- Last close
- $66.64
- Period change
- -9.51%
- Period low
- $66.64
- Period high
- $76.37
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $68.10 | $68.48 | $65.75 | $66.64 | 1.26M |
| Sep 14, 2026 | $70.00 | $70.00 | $68.03 | $68.50 | 920.05K |
| Sep 11, 2026 | $71.41 | $71.41 | $68.35 | $69.76 | 784.21K |
| Sep 10, 2026 | $72.01 | $73.50 | $70.60 | $70.65 | 945.89K |
| Sep 9, 2026 | $75.10 | $75.6275 | $72.00 | $73.32 | 941.85K |
| Sep 8, 2026 | $74.10 | $77.755 | $74.00 | $75.44 | 867.67K |
| Sep 4, 2026 | $74.67 | $75.63 | $73.64 | $74.19 | 607.43K |
| Sep 3, 2026 | $73.41 | $76.63 | $72.99 | $76.37 | 691.27K |
| Sep 2, 2026 | $72.38 | $74.7201 | $70.7043 | $72.74 | 353.96K |
| Sep 1, 2026 | $70.41 | $72.73 | $70.0001 | $71.75 | 334.11K |
| Aug 31, 2026 | $71.42 | $72.175 | $70.00 | $71.38 | 381.52K |
| Aug 28, 2026 | $74.01 | $74.835 | $71.20 | $72.52 | 579.72K |
| Aug 27, 2026 | $74.00 | $75.325 | $73.19 | $74.55 | 340.35K |
| Aug 26, 2026 | $74.21 | $74.9695 | $73.61 | $73.77 | 450.25K |
| Aug 25, 2026 | $74.98 | $76.79 | $74.06 | $74.96 | 414.91K |
| Aug 24, 2026 | $73.01 | $74.40 | $70.925 | $73.69 | 747.95K |
| Aug 21, 2026 | $75.10 | $76.2344 | $72.825 | $74.02 | 614.08K |
| Aug 20, 2026 | $76.08 | $76.5253 | $73.19 | $74.53 | 438.57K |
| Aug 19, 2026 | $75.00 | $76.215 | $73.4299 | $76.08 | 731.78K |
| Aug 18, 2026 | $72.00 | $74.91 | $70.48 | $73.64 | 565.52K |
Latest NKTR news
The latest Smart Investors Daily articles mentioning NKTR.
Stock researchCompany · Overview
NKTR research
Overview
Company profile and research snapshot.
Company profile
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $121.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | BTIG | Buy | — |
| Sep 9, 2026 | BTIG | Buy | — |
| Aug 21, 2026 | JP Morgan | Neutral | — |
| Jul 22, 2026 | Canaccord Genuity | Buy | — |
| May 11, 2026 | Wedbush | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Sep 8, 2026
Nektar Therapeutics Enters Quiet Period Beginning September 8 Until Public Announcement Of Data From 24-Week Off Treatment Follow-Up Period Of Phase 2b REZOLVE-AA Study Of Rezpegaldesleukin In Patients With Alopecia Areata
-SEC Filing
Yahoo · Aug 28, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics (NASDAQ: NKTR) today announced that, on August 20, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase an aggregate of 25,200 shares of its common stock and 5,000 restricted stock units (RSUs) to eleven newly-hired employees under Nektar's 2025 Inducement Plan.
Yahoo · Aug 27, 2026
Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test
On August 13, Nektar Therapeutics (NASDAQ:NKTR) held its second-quarter earnings call and laid out where its lead drug candidate stands after years of development. Rezpegaldesleukin, known as rezpeg, is now enrolling patients in Phase 3 trials for two separate autoimmune conditions, atopic dermatitis and alopecia areata. Management framed the quarter around two numbers that matter […]
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
